Clinical Trial Update: Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase II study evaluating the combination of pembrolizumab and lenvatinib in advanced adrenocortical carcinoma, currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING